Andy Plump teams with MD Anderson on the race to cell therapy 2.0 — and they’re already planning a pivotal

John Carroll

Editor & Founder

Takeda R&D chief Andy Plump has picked his contender in the race to create cell therapy 2.0, and he’s created his own breakthrough oncology path to hustle it through a near-term pivotal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Andy Plump teams with MD Anderson on the race to cell therapy 2.0 — and they’re already planning a pivotal

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

The next generation of AI biotechs is here. Can they deliver on the hype?

Bristol Myers to shutter Bay Area cell therapy R&D facility as it eliminates jobs and costs

AbbVie beats first-quarter expectations, but Humira guidance leaves analysts confused

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag

Sanders presses pharma leaders to change stance on Pandemic Accord proposals

Andy Plump teams with MD An­der­son on the race to cell ther­a­py 2.0 — and they’re al­ready plan­ning a piv­otal

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

more like this

The next gen­er­a­tion of AI biotechs is here. Can they de­liv­er on the hype?

Bris­tol My­ers to shut­ter Bay Area cell ther­a­py R&D fa­cil­i­ty as it elim­i­nates jobs and costs

Ab­b­Vie beats first-quar­ter ex­pec­ta­tions, but Hu­mi­ra guid­ance leaves an­a­lysts con­fused

UCB makes ma­jor man­age­ment changes; Bris­tol My­ers’ ADC part­ner tops list of new CEOs

Up­dat­ed: FDA ap­proves Pfiz­er’s he­mo­phil­ia B gene ther­a­py, with $3.5M price tag

Sanders press­es phar­ma lead­ers to change stance on Pan­dem­ic Ac­cord pro­pos­als

Andy Plump teams with MD Anderson on the race to cell therapy 2.0 — and they’re already planning a pivotal

The next generation of AI biotechs is here. Can they deliver on the hype?

Bristol Myers to shutter Bay Area cell therapy R&D facility as it eliminates jobs and costs

AbbVie beats first-quarter expectations, but Humira guidance leaves analysts confused

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag

Sanders presses pharma leaders to change stance on Pandemic Accord proposals